Showing results (481-490 of 539) with videos related to

Sort By:
Pageof 54
Neurology|April 29, 2021
Long-term Efficacy and Safety of Erenumab: Results From 64 Weeks of the LIBERTY StudyPeter J Goadsby, Uwe Reuter, Michel Lanteri-Minet, et al.
The Lancet. Neurology|April 19, 2025
Long-term safety, tolerability, and efficacy of eptinezumab in chronic cluster headache (CHRONICLE): an open-label safety trialCristina Tassorelli, Rigmor H Jensen, Peter J Goadsby, et al.
Cephalalgia : an International Journal of Headache|June 15, 2023
Two-year, real-world erenumab persistence and quality of life data in 82 pooled patients with abrupt onset, unremitting, treatment refractory headache and a migraine phenotype: New daily persistent headache or persistent post-traumatic headache in the majority of casesAlina Buture, Esther M Tomkins, Arif Shukralla, et al.
Plos One|February 9, 2023
Design and performance analysis of salinity gradient solar pond under different climatic and soil conditionsMuhammad Ihsan Shahid, Muhammad Asim, Muhammad Farhan, et al.
The Lancet. Neurology|October 10, 2014
Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trialDavid W Dodick, Peter J Goadsby, Stephen D Silberstein, et al.
The Journal of Headache and Pain|January 16, 2023
Medium-term real-world data for erenumab in 177 treatment resistant or difficult to treat chronic migraine patients: persistence and patient reported outcome measures after 17-30 monthsEmma Troy, Arif A Shrukalla, Alina Buture, et al.
Cephalalgia : an International Journal of Headache|September 2, 2025
Migraine stigma and general knowledge of migraine: A cross-sectional European surveyPeter J Goadsby, Elena Ruiz de la Torre, Antoinette Maassen van den Brink, et al.
Neurology|July 9, 2020
One-year sustained efficacy of erenumab in episodic migraine: Results of the STRIVE studyPeter J Goadsby, Uwe Reuter, Yngve Hallström, et al.
Neurology and Therapy|November 10, 2023
Comparing the Efficacy and Safety of Galcanezumab Versus Rimegepant for Prevention of Episodic Migraine: Results from a Randomized, Controlled Clinical TrialTodd J Schwedt, Tina M Myers Oakes, James M Martinez, et al.
Neurology|April 26, 2024
Efficacy and Safety of Erenumab in Participants With Episodic Migraine in Whom 2-4 Prior Preventive Treatments Had Failed: LIBERTY 3-Year StudyUwe Reuter, Peter J Goadsby, Michel D Ferrari, et al.
Pageof 54